Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium breve is used to support the management of Inflammatory Bowel Disorders (IBD), such as Crohn’s disease and ulcerative colitis, with a basis in emerging scientific evidence. Several clinical studies and preclinical investigations suggest that B. breve may help modulate gut inflammation and restore microbial balance, both of which are disrupted in IBD patients. In animal models, administration of B. breve has been associated with reduced intestinal inflammation, improved epithelial barrier function, and suppressed pro-inflammatory cytokine production. Human studies, though limited, have shown that B. breve supplementation can be safe and may lead to improvements in clinical symptoms and inflammatory markers in IBD patients. One randomized controlled trial found that a mixture containing B. breve reduced recurrence of ulcerative colitis compared to placebo. The proposed mechanisms include enhancement of the gut mucosal barrier, modulation of immune responses (e.g., increasing anti-inflammatory cytokines), and competitive inhibition of pathogenic bacteria. However, the evidence base is still modest: most trials are small, use probiotic combinations rather than B. breve alone, and longer-term outcomes are unclear. Thus, while there is scientific validation for its adjunctive use in IBD, more robust, large-scale studies are needed. The current evidence supports a cautious but optimistic perspective on B. breve as part of a broader probiotic strategy in IBD management.

More about Bifidobacterium breve
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Bifidobacterium breve

Products containing Bifidobacterium breve